PMID- 34650920
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced 
      Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis.
PG  - 736113
LID - 10.3389/fonc.2021.736113 [doi]
LID - 736113
AB  - BACKGROUND: At present, chemotherapy is still the primary treatment for advanced 
      biliary tract carcinoma, but it is challenging to balance the efficacy and side 
      effects. Network meta-analysis (NMA) is a better way to identify the protocol, 
      and the advantage is that it can be combined with direct and indirect evidence to 
      judge the best treatment regimens. Therefore, we conducted NMA on the searched 
      randomized controlled trials (RCTs). METHODS: NMA was conducted regarding the 
      searched RCTs by comparing progression-free survival (PFS), overall survival 
      (OS), objective remission rates (ORRs), and adverse events (AEs) of different 
      chemotherapy protocols. RESULTS: We screened 24 studies that met the inclusion 
      criteria for further analysis. Compared with other regimens, the best supportive 
      care (BSC) or FUFA protocol has a worse OS. Folfox4, GEMOX+erlotinib, and C+GEMOX 
      can improve patients' PFS compared with BSC. Patients receiving GP+cediranib 
      protocol have higher ORRs. There was reduced neutropenia grade >/=3 when adopting 
      GP+cediranib, GS, C+GEMOX, RAM+GP, and MER+GP than when using FUFA protocol. The 
      probability of vomiting of XELOX is lower than that of GEM+XELOX. There is a 
      lower diarrhea incidence of XELOX than that of GEMOX+erlotinib. The results of 
      cluster grade analysis illustrated that GEMOX+erlotinib owned a higher ORR and a 
      higher surface under the cumulative ranking (SUCRA) of neutropenia and vomiting 
      but also had a lower SUCRA of diarrhea and fatigue. Meanwhile, both GEMOX and 
      C+GEMOX have a better ORR and a higher AE SUCRA. CONCLUSION: The NMA demonstrated 
      that chemotherapy combined with targeted therapy has better efficacy and lower 
      incidence of AEs than chemotherapy alone.
CI  - Copyright (c) 2021 Jiang, Zeng, Zeng, Liu, Qiu, Li, Tang, Mo, Du and Ma.
FAU - Jiang, Yanfeng
AU  - Jiang Y
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Zeng, Zhiming
AU  - Zeng Z
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Zeng, Jie
AU  - Zeng J
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Liu, Cuizhen
AU  - Liu C
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Qiu, Jinfeng
AU  - Qiu J
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Li, Ye
AU  - Li Y
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Tang, Jing
AU  - Tang J
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Mo, Ning
AU  - Mo N
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Du, Lihua
AU  - Du L
AD  - Department of Oncology, Liuzhou People's Hospital, Liuzhou, China.
FAU - Ma, Jie
AU  - Ma J
AD  - Department of Oncology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, China.
LA  - eng
PT  - Systematic Review
DEP - 20210928
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8507323
OTO - NOTNLM
OT  - adverse events
OT  - biliary tract carcinoma
OT  - chemotherapies
OT  - first-line
OT  - network meta-analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/16 06:00
MHDA- 2021/10/16 06:01
PMCR- 2021/01/01
CRDT- 2021/10/15 06:38
PHST- 2021/07/04 00:00 [received]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2021/10/15 06:38 [entrez]
PHST- 2021/10/16 06:00 [pubmed]
PHST- 2021/10/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.736113 [doi]
PST - epublish
SO  - Front Oncol. 2021 Sep 28;11:736113. doi: 10.3389/fonc.2021.736113. eCollection 
      2021.